OBJECTIVE: To compare outcomes of patients with clinical nodal melanoma metastases that occurred without a detectable primary tumor (melanoma of unknown primary site; MUP) with those with a known primary site (KPM). METHODS: We included data from 459 consecutive patients treated from 1994 to 2007 with radical therapeutic lymph node dissection (LND; stage IIIB, C) due to clinically palpable and pathologically confirmed lymph node metastases (229 axillary; 230 ilioinguinal). The median follow-up was 49 months. RESULTS: LND was performed in 59 cases (12.9%; 29 men, 30 women) due to MUP nodal metastases, including 33 axillary (14.4%) and 26 ilioinguinal (11.3%). In the MUP group, the 3- and 5-year survival rates were 48% and 41%, respectively. Similar rates were observed in patients with KPM, even with matched-pair analyses. Established prognostic factors (number of metastatic nodes, p=.005; extracapsular extension of metastases, p=.002) influenced survival in the MUP group. Relapses occurred in 31 (53%) and 299 (74.7%) cases in the MUP and KPM groups, respectively. CONCLUSIONS: Survival rates in the MUP and KPM groups were similar, and the same prognostic factors affected both. Thus, all MUP cases should be treated as standard stage III melanomas.
OBJECTIVE: To compare outcomes of patients with clinical nodal melanoma metastases that occurred without a detectable primary tumor (melanoma of unknown primary site; MUP) with those with a known primary site (KPM). METHODS: We included data from 459 consecutive patients treated from 1994 to 2007 with radical therapeutic lymph node dissection (LND; stage IIIB, C) due to clinically palpable and pathologically confirmed lymph node metastases (229 axillary; 230 ilioinguinal). The median follow-up was 49 months. RESULTS: LND was performed in 59 cases (12.9%; 29 men, 30 women) due to MUP nodal metastases, including 33 axillary (14.4%) and 26 ilioinguinal (11.3%). In the MUP group, the 3- and 5-year survival rates were 48% and 41%, respectively. Similar rates were observed in patients with KPM, even with matched-pair analyses. Established prognostic factors (number of metastatic nodes, p=.005; extracapsular extension of metastases, p=.002) influenced survival in the MUP group. Relapses occurred in 31 (53%) and 299 (74.7%) cases in the MUP and KPM groups, respectively. CONCLUSIONS: Survival rates in the MUP and KPM groups were similar, and the same prognostic factors affected both. Thus, all MUP cases should be treated as standard stage III melanomas.
Authors: James P De Andrade; Paul Wong; Michael P O'Leary; Vishwas Parekh; Arya Amini; Hans F Schoellhammer; Kim A Margolin; Michelle Afkhami; Laleh G Melstrom Journal: Ann Surg Oncol Date: 2020-09-09 Impact factor: 5.344
Authors: Benjamin Weide; Christine Faller; Margrit Elsässer; Petra Büttner; Annette Pflugfelder; Ulrike Leiter; Thomas Kurt Eigentler; Jürgen Bauer; Friedegund Meier; Claus Garbe Journal: PLoS One Date: 2013-06-25 Impact factor: 3.240
Authors: Sebastiaan P Prens; Augustinus P T van der Ploeg; Alexander C J van Akkooi; Cornelis A G M van Montfort; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont; Cornelis Verhoef Journal: Ann Surg Oncol Date: 2011-05-25 Impact factor: 5.344
Authors: Aleksandra Gos; Monika Jurkowska; Alexander van Akkooi; Caroline Robert; Hanna Kosela-Paterczyk; Senada Koljenović; Nyam Kamsukom; Wanda Michej; Arkadiusz Jeziorski; Piotr Pluta; Cornelis Verhoef; Janusz A Siedlecki; Alexander M M Eggermont; Piotr Rutkowski Journal: Ann Surg Oncol Date: 2014-05-28 Impact factor: 5.344
Authors: Bożena Cybulska-Stopa; Marta Skoczek; Marek Ziobro; Tomasz Switaj; Sławomir Falkowski; Tadeusz Morysiński; Marcin Hetnał; Ida Cedrych; Piotr Rutkowski Journal: Contemp Oncol (Pozn) Date: 2013-01-04
Authors: Elke J A H van Beek; Alfons J M Balm; Omgo E Nieweg; Olga Hamming-Vrieze; Peter J F M Lohuis; W Martin C Klop Journal: Cancers (Basel) Date: 2015-08-10 Impact factor: 6.639